Study suggests link between weight-loss drugs, eye disorder (Il Sole 24 Ore Radiocor) - New York, 04 Jul - Novo Nordisk investors appeared unphased by a report suggesting an association between weight-loss drugs and a rare eye disorder as shares in the drugmaker traded in the green.

According to a study carried out by Harvard Medical School, Semaglutide, which is present in weight-loss drugs including Novo Nordisk's Ozempic and Wegovy, might be associated with increased risk of nonarteritic anterior ischemic optic neuropathy (NAION).

"This study's findings suggest an association between semaglutide and NAION. As this was an observational study, future study is required to assess causality," the report said.

At 1324 GMT Novo Nordisk shares were up 0.44%.

AAA-Sje

(RADIOCOR) 04-07-24 15:30:04 (0432) 5 NNNN